Spanish Hidradenitis Suppurativa Registry (REHS) of the Spanish Academy of Dermatology and Venereology: description and data from its first year of operation.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carnero González L, Garcias-Ladaria J G, Rivera-Díaz R, Bassas Vila J, Salgado-Boquete L, Masferrer E, Molina-Leyva A, Perandones-González H, Muñiz de Lucas A, Pascual J C, Mendieta-Eckert M, Martín-Ezquerra G, Garbayo-Salmons P, Nieto-Benito L M, Romaní J, Escutia B, Herrera-Acosta E, Vilarrasa E, Luque-Luna M, Pericet Fernández L M, Rodríguez García F, No Pérez N, Gracia-Darder I, Falkenhain-López D, Mora-Fernández V, Oro-Ayude M, Corral-Magaña O, Grau-Pérez M, Martorell A, en nombre del Grupo de Trabajo REHS
Аннотация
METHODS: The REHS is a prospective, multicenter, observational study that collects the clinical and epidemiological characteristics of patients with HS, as well as the safety and effectiveness of the medical and surgical treatments received.
RESULTS: Between June 2023 and June 2024, 359 patients were recruited from 23 Spanish centers. The average age of the patients is 37 years, and 53% of them are women. Over 70% of the patients are smokers or former smokers. One third have a family history of HS. The most frequent sites of disease onset are the axillae and groin. Median baseline IHS4 at recruitment was 4 (p25-p75=1-9), HiSQOL was 20 (p25-p75=8-36), and BMI was 27.3 (p25-p75=24-33.2). At least 82% of patients have received antibiotic therapy for their disease, and almost 20% a biologic drug.
CONCLUSIONS: We present data from the first patients enrolled in the REHS, which will allow for the generation of evidence on the natural course of the disease, as well as the effectiveness and safety of treatments in HS.